Dr. John Harrison
Dr. John John Harrison is Interim Director of the Centre for Radiation, Chemical and Environmental Hazards (CRCE) within the Health Protection Agency (HPA), Chilton, Didcot, United Kingdom.
Dr. Harrison joined the National Radiological Protection Board (NRPB) in 1974 having gained a B.Sc. in Biochemistry at University College, Wales, and Ph.D. in Biochemistry at St. George's Hospital Medical School, University of London. His doctoral thesis dealt with the biological behaviour of indium and gallium radioisotopes and their use in radiopharmaceuticals. For many years, he was Head of the Radionuclide Effects Group of Radiation Effects Department within NRPB. More recently, he has been Head of Dose Assessments Department and later Deputy Director for Research in the same institute which has a broadened remit as the Centre for Radiation, Chemical and Environmental Hazards (CRCE) of the Health Protection Agency (HPA).
Dr. Harrison has substantially contributed to the work of the International Commission on Radiological Protection (ICRP) over many years and is currently secretary and vice-chairman of ICRP Committee 2, a member of three Task Groups, on internal Dosimetry, Alpha epidemiology and Stem cells, and chairman of a Task Group on the use of Effective dose.
Dr. Harrison was a member of the UK Government Committee Examining Radiation Risks of Internal Emitters (CERRIE), which was set up to examine claims that radiation risks from internal emitters are being underestimated by orders of magnitude. He is coordinator of the EU FP7 SOLO project (full title: Epidemiological Studies of Exposed Southern Urals Populations). This project runs until 2015 and is concerned with establishing dose - response relationships for cancer and non-cancer disease induced by radionuclides and external radiation as a result of working at the Russian Mayak plutonium production plant or living near to the Techa River into which radioactive waste was discharged. He is also HPA representative on the Board of the Multidisciplinary European Low Dose Initiative Association (MELODI), currently supported by the EU Network of Excellence, DoReMi.
Dr. Harrison has been Representative of the United Kingdom since 2013 and member of the UK delegation since 2011.